From Marketbeat:



Enliven Therapeutics, Inc. CEO Samuel Kintz recently sold thousands of shares of the company’s stock, a move that has resulted in the stock price dropping by 2.4%. This comes after a recent quarterly earnings report that displayed a lower than expected EPS. However, despite this drop, Enliven Therapeutics is still poised to perform well in the financial market. During the recent months, several hedge funds have both bought and sold shares of the company, indicating a fluctuation in the market.

Additionally, Enliven Therapeutics is currently focusing on the development of small molecule inhibitors to help cancer patients. Their lead product candidates, ELVN-001 and ELVN-002, are currently in the trial phases. Although Enliven Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe there are five other stocks that are better buys. Overall, Enliven Therapeutics is positioned to continue its work and development in the cancer research and treatment field, despite the recent stock sale by its CEO.



Read more: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 8,175 Shares